Parents of children with spinal muscular atrophy (SMA), a rare disease, welcomed the announcement by the Indian pharma ...

Natco Pharma updates on Risdiplam launch in India, Delhi High Court denies Roche's injunction plea, pricing set at ₹15,900.

The stock rose 2.95 per cent to hit a high of Rs 789. It was last seen trading 1.44 per cent up at Rs 777.45. At this price, ...

Natco Pharma started in Hyderabad with an investment of ₹3.3 million in 1981 and 20 employees working at a single unit. Today ...

The main industry in which Natco Pharma Ltd operates is Pharmaceuticals - Indian - Bulk Drugs & Formln. Auditor/Auditors for Natco Pharma Ltd is/are B S R & Co. In the main management, V C ...

Affordable generic version of SMA drug Risdiplam soon available in India, offering hope to patients and activists.

The high court noted that SMA is a debilitating disease which has no cure, and the only approved drug, Risdiplam, marketed ...

Telangana: Natco Pharma has announced the superannuation of Dr Ramesh Dandala, Executive Vice President - Technology Transfer ...

The Delhi High Court on Monday refused to allow a lawsuit filed by Swiss pharmaceutical company Roche that sought to restrain Indian drug maker Natco Pharma from manufacturing Risdiplam ...

Natco Pharma plans to launch generic Risdiplam pending Delhi High Court decision, offering discounts to patients.